How profitable is Milestone Scientific Inc. (MLSS)?

In FY 2025 (10-K), MLSS converted $9.0M of revenue into a 71.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / MLSS / financials

LFWD (32) HSCS (38) MYO (31) COCH (36) ⌘ Pro Terminal →

Milestone Scientific Inc. (MLSS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.30 -3.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.30

Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $27.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MLSS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.30 (-3.30% 1D, market cap $27.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, MLSS ranks #467 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MLSS compare to LFWD and HSCS in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MLSS?

▼

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.30 (-0.78%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLSS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY MLSS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (35.4) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.34+0% Next Q

Q2 (-2Q)

Grade D$0.34-11.8% Next Q

Q3 (-1Q)

Grade D$0.30+0% Next Q

Current

Grade D-$0.30-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MLSS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MLSS currently carries a cautious 40/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.39) and Max Pain ($0.32) forces dealer call-delta covering toward $0.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MLSS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MLSS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MLSS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $19.9M

FY24

Rev $8.6M

FY25

Rev $9.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$9.0M	71.4%	-63.5%	$5.7M	-$2.9M	-45%
FY 2024	$8.6M	74.6%	-78.3%	$4.7M	-$2.9M	-45%
FY 2023	$19.9M	71.4%	-35.7%	$6.9M	-$5.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLSS)

✓Walkthrough of MLSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MLSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.29%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.31H $0.31L $0.30C $0.30VOL 42.0K

RES: $0.67SUP: $0.28SMA50: $0.39SMA200: $0.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLSS Butterfly Map → + Track MLSS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-14.0%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MLSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLSS)

Health Care Rank #467 of 1015 ⚔️ LFWD vs MLSS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLSS vs. LFWD, HSCS, MYO, COCH)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #467 by composite RQD confidence (40/100, grade D-) and #806 by equity capitalization ($27.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. MLSS currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MLSS ACTIVE Milestone Scientific Inc.	D-	40/100	5.0x	71.4%	-35.0%	-3.30%	$27.6M	Benchmark Subject
LFWD Lifeward Ltd.	E	32/100	—	96.0%	-35.0%	+0.71%	$16.9M	/lfwd-vs-mlss →
HSCS HeartSciences Inc.	D-	38/100	—	59.1%	-35.0%	-8.31%	$16.0M	/hscs-vs-mlss →
MYO Myomo Inc.	E	31/100	—	65.7%	-35.0%	-4.61%	$49.1M	/myo-vs-mlss →
COCH Envoy Medical Inc. (Class A)	D-	36/100	—	-30.0%	-35.0%	+2.00%	$51.3M	/coch-vs-mlss →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000855683 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M , and -54.9% cumulative change since FY2023) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	$5.7M	-$2.9M	-$2.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$8.6M	$4.7M	-$2.9M	-$2.9M	$9.8M	—
FY2023 (FY)	2023-12-31	$19.9M	$6.9M	-$5.3M	-$5.3M	—	—

3. MLSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MLSS compare to LFWD and HSCS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MLSS?

Where is MLSS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLSS last traded at $0.30 (-3.30% on volume of 41,985 shares), positioning the stock -23.08% below its 50-day simple moving average ($0.39) and -14.29% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 22.2% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

Direct Sub-Reports: MLSS RQD Cockpit MLSS 12M Forecast MLSS Earnings & Move MLSS Dividends & DRIP MLSS Insiders & 13F MLSS Whale Options MLSS Profit Sankey MLSS News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MLSS — Milestone Scientific Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Milestone Scientific Inc. (MLSS) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.30 (-3.30% 1D, market capitalization $27.6M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 71.4%, operating margin of -60.0%, and free cash flow yield of -10.27%.
Whale 13F & Options Flow (12/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Milestone Scientific Inc. Is a NYSE-listed issuer classified in the Health Care sector and Industrial Specialties industry,. The company reported revenue of $9.0M for FY 2025 and $8.6M for FY 2024. Per the market data, gross margin is 71.4%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported $9.0M in annual revenue (up from $8.6M in FY2024, +4.0% YoY) and $5.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.9M revenue, $6.9M net income) through FY2025, MLSS scaled operating cash flow to -$2.9M and free cash flow to -$2.9M, backed by $7.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.27% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.22 – $0.58 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 5.0x trailing P/E against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream supplier dependencies, downstream customer concentration, or 2nd-order bottlenecks.

Key Question #1: Can MLSS sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $9.0M and free cash flow of -$2.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is MLSS's 4.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MLSS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Milestone Scientific Inc. (MLSS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MLSS Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 22h ago

Milestone Scientific(MLSS) Stock Options Chain | Quotes & News

Moomoo report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Milestone Scientific, Inc. (MLSS) Seasonal returns chart

Yahoo Finance UK report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Milestone Scientific, Inc. Estimates – AMEX:MLSS

TradingView report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Reaching 2% of estimated U.S. epidural procedures could mean about $33 million a year in potential single-use sales.

Stock Titan report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST WBOC TV • 1d ago

Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures

WBOC TV report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's After-Market Session - Flyte Aviation (AMEX:VJET), Option Care H

Benzinga report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Retractable Technologies, Inc. (RVP) Seasonal returns chart

Yahoo Finance UK report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MLSS Bull vs. Bear Conversation Board — What's Your Call at $0.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MLSS 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.38 (+26.7%)

📌 Pinned Debate

Low headline valuation (P/E TTM of 5, Forward P/E of 4.7) combined with a GREEN-flagged CompuFlo® commercial growth catalyst across 30

Picked up a starter position in MLSS in my $100K Virtual Cash book at $0.30. Low headline valuation (P/E TTM of 5, Forward P/E of 4.7) combined with a GREEN-flagged CompuFlo® commercial growth catalyst across 30 million+ annual global epidural procedures.. Trading inside a $0.22–$0.58 52-week range with -10.27% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 12/20 institutional whale-flow stock at $0.30 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.24 (-20.0%)

Spot @ $0.30

Negative ROIC of -35%, negative free cash flow in each reported year, and cash falling from $3.3M to $1.1M, with a -60% operating margi

Negative ROIC of -35%, negative free cash flow in each reported year, and cash falling from $3.3M to $1.1M, with a -60% operating margin that the data does not reconcile against positive net income.. Look at the math on MLSS: paying 5.0x trailing P/E for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $0.26 before getting long.